New combo therapy aims to outsmart drug-resistant lung cancer

NCT ID NCT05845671

Ongoing Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jan 16, 2026 · Last updated May 12, 2026 · Updated 17 times

Summary

This early-phase study tests a new drug, amivantamab, combined with standard targeted therapies (TKIs) in 12 adults with advanced non-small cell lung cancer that has specific gene changes (ALK, ROS1, or RET). The cancer has stopped responding to current treatments. The goal is to find the safest dose and see if the combination can shrink tumors by blocking escape pathways that cancer cells use to resist treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

City of Hope Cancer Center

Duarte, California, 91010, United States
Outpatient CTRC

Aurora, Colorado, 80045, United States
University of Colorado Hospital

Aurora, Colorado, 80045, United States
University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States

Conditions

Explore the condition pages connected to this study.

LUNG CANCER NON SMALL CELL LUNG CANCER